CalciMedica to Host Symposium on Novel Therapies for Acute Kidney Injury at Vicenza Course 2025

CalciMedica's Upcoming Symposium at the 43rd Vicenza Course

CalciMedica Inc., a clinical-stage biopharmaceutical company based in La Jolla, California, is making waves in the medical community with its announcement of a symposium focused on innovative therapies for acute kidney injury (AKI). Scheduled for June 24 to 26, 2025, at the prestigious 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting in Vicenza, Italy, this event aims to spotlight the company's lead product, Auxora, which is designed to modulate calcium release-activated channels in critical inflammatory and immunologic conditions.

Dr. Sudarshan Hebbar, CalciMedica’s Chief Medical Officer, will kick off the symposium with an insightful presentation titled "Overview of Calcium Release-Activated Calcium (CRAC) Channels" on June 24, from 1:45 PM to 2:00 PM CEST. This presentation promises to provide attendees with a detailed understanding of CRAC channels and their significance in managing acute and chronic inflammatory responses.

Following Dr. Hebbar, renowned nephrologist Dr. Javier Neyra from the University of Alabama will delve into the "Role of IL-17 in the Pathophysiology of AKI," shedding light on emerging findings related to this critical cytokine. This presentation will take place from 2:00 PM to 2:20 PM CEST, emphasizing the evolving perspectives on AKI treatment.

Lastly, Dr. Lakhmir Chawla, Clinical Professor of Medicine at the University of California San Diego and Chief Medical Officer at ExThera Medical, will discuss the ongoing KOURAGE clinical trial (NCT06374797) from 2:20 PM to 2:35 PM CEST, which is exploring the effects of Auxora in AKI patients suffering from acute hypoxemic respiratory failure.

Attendees can expect to gain invaluable insights into cutting-edge research and development in biopharmaceutical therapies. To further enhance accessibility, CalciMedica will provide webcasts of these presentations post-event, available through their investor relations website.

CalciMedica is committed to advancing healthcare outcomes through their unique approach to calcium-induced immunomodulation. The company focuses on developing therapies that inhibit CRAC channels, providing an innovative solution targeting inflammatory and immunologic diseases for which traditional treatments are lacking. Their flagship product, Auxora, has shown promising efficacy results in multiple clinical trials and has been tolerated well in over 350 critically ill patients.

With ongoing Phase 2 studies investigating Auxora's safety and efficacy in conditions such as acute pancreatitis and COVID-19 pneumonia, CalciMedica is positioning itself as a leader in therapeutic innovation for acute kidney injury and related inflammatory conditions. The symposium at Vicenza will serve as an important platform to disseminate knowledge and foster collaboration among researchers and clinicians, ultimately seeking to improve patient outcomes in critical care nephrology.

For additional information about their innovative research and future events, interested parties can visit CalciMedica's official website.